Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

Pain & musculoskeletal carePRM 0023
Dosage formTablets
Oral

(6S) 5-Methyltetrahydrofolic Acid, Glucosamine Salt (MD)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Haematinic & nutritional supplement
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5585
Dosage formTopical cream
Topical

/ 15 gm, Clobetasol Propionate 0.5% w/w, Iodochlorhydroxyquinoline 1% w/w, Ketoconazole 2% w/w, Neomycin 0.1% w/w, Tolnaftate 1% w/w

Route
Topical
Formulation type
Topical semi-solid cream
Pharmacological class
Aminoglycoside antibiotic + Azole antifungal + Corticosteroid + Hydroxyquinoline antimicrobial + Thiocarbanilate antifungal
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Haematology & thrombosisPRM 4618
Dosage formHard-gelatin capsules
Oral

1, 2-Dimethyl-3-Hydroxypyrid-4-one 250 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Iron chelator
Manufacturing stream
Non-beta-lactam
BCS class
Class I
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Haematology & thrombosisPRM 4619
Dosage formHard-gelatin capsules
Oral

1, 2-Dimethyl-3-Hydroxypyrid-4-one 500 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Iron chelator
Manufacturing stream
Non-beta-lactam
BCS class
Class I
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Nutrition & supportive carePRM 4620
Dosage formHard-gelatin capsules
Oral

5-Hydro Anthranilic Acid Hcl 0.2 mg, Biotin 30 mcg, Cholecalciferol 400 IU, Cyanocobalamin 2.5 mcg, DL-Methionine 18.4 mg, Folic Acid 0.50 mg, L-Arginine Hcl 13.28 mg, L-Histidine Hcl H2O 3.71 mg, L-Isoleucine 5.9 mg, L-Leucine 18.3 mg, L-Lysine Hcl 25 mg, L-Phenylalanine 5.0 mg, L-Threonine 4.2 mg, L-Tryptophan 5.0 mg, L-Valine 6.7 mg, Natural Betacarotene With Other Mixed Carotenoids 1000 mcg, Nicotinamide 25 mg, Pyridoxine Hcl 1.5 mg, Zinc Ascorbate 50 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Vitamin D / vitamin D analogue + Amino acid / metabolic nutritional supplement + Vitamin / mineral supplement + Mineral supplement
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 5177
Dosage formSyrup
Oral

Abacavir 20 mg / ml

Route
Oral
Formulation type
Oral liquid syrup
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2576
Dosage formTablets
Oral

Abacavir 300 mg, Lamivudine 150 mg, Zidovudine 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2577
Dosage formTablets
Oral

Abacavir 60 mg, Lamivudine 30 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2578
Dosage formTablets
Oral

Abacavir 600 mg, Atazanavir 300 mg, Lamivudine 300 mg, Ritonavir 100 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
HIV protease inhibitor + Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2579
Dosage formTablets
Oral

Abacavir 600 mg, Dolutegravir 50 mg, Lamivudine 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
HIV integrase inhibitor + Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2580
Dosage formTablets
Oral

Abacavir 600 mg, Lamivudine 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2581
Dosage formTablets
Oral

Abacavir Sulfate 60 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2582
Dosage formTablets
Oral

Abacavir Sulphate 120 mg, Lamivudine 60 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Veterinary productsPRM 2583
Dosage formTablets
Oral

Abamectin 0.00025 g, Praziquantel 0.0065 g

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Veterinary antiparasitic + Anthelmintic
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Haematology & thrombosisPRM 5178
Dosage formSyrup
Oral

Absolute Alcohol 5% v/v, Biotin 300 mcg, Chromium 25 mcg, Copper 0.45 mg, Elemental Iodine 75 mcg, Elemental Zinc 7.5 mg, Iron 18 mg, L-Lysine MonoHcl 50 mg, Manganese 1.0 mg, Methylcobalamin 500 mcg, Niacinamide 45 mg, Selenium 40 mcg, Vitamin B6 1.5 mg / 15 ml

Route
Oral
Formulation type
Oral liquid syrup
Pharmacological class
Iron replacement / haematinic + Amino acid / metabolic nutritional supplement + Vitamin / mineral supplement + Mineral supplement
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Dermatology & topical carePRM 5593
Dosage formTopical gel
Topical

Absolute Alcohol 50 mg, Menthol 50 mg, Methyl Salicylate 100 mg, Thiocolchicoside 0.25% w/w

Route
Topical
Formulation type
Topical semi-solid gel
Pharmacological class
Counterirritant / topical analgesic + Skeletal muscle relaxant
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Topical
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 0025
Dosage formTablets
Oral

Acarbose 100 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Local
Drugs Rules status
Schedule H cautionRule 96(1)(xi)
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 282
Diabetes & endocrinologyPRM 2590
Dosage formTablets
Oral

Acarbose 25 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Alpha-glucosidase inhibitor + Biguanide antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Diabetes & endocrinologyPRM 0024
Dosage formTablets
Oral

Acarbose 50 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Local
Drugs Rules status
Schedule H cautionRule 96(1)(xi)
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 282
Diabetes & endocrinologyPRM 2591
Dosage formTablets
Oral

Acarbose 50 mg, Metformin 500 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Alpha-glucosidase inhibitor + Biguanide antidiabetic
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Respiratory & allergyPRM 1452
Dosage formSyrup
Oral

Acebrophylline 10 mg

Route
Oral
Formulation type
Oral liquid syrup
Pharmacological class
Respiratory & allergy agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 890
Respiratory & allergyPRM 2146
Dosage formHard-gelatin capsules
Oral

Acebrophylline 100 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Respiratory & allergy agent
Manufacturing stream
Non-beta-lactam
BCS class
Class I
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 153
Respiratory & allergyPRM 0026
Dosage formTablets
Oral

Acebrophylline 100 mg Uncoated

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Respiratory & allergy agent
Manufacturing stream
Non-beta-lactam
BCS class
Class I
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Respiratory & allergyPRM 0028
Dosage formTablets
Oral

Acebrophylline 100 mg, N-Acetylcysteine 600 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Mucolytic & expectorant
Manufacturing stream
Non-beta-lactam
BCS class
Class I
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product